E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 11 940 KRW 0.59% Market Closed
Market Cap: 436.2B KRW
Have any thoughts about
EuBiologics Co Ltd?
Write Note

EuBiologics Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

EuBiologics Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
E
EuBiologics Co Ltd
KOSDAQ:206650
Cash from Operating Activities
â‚©21B
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash from Operating Activities
â‚©745.5B
CAGR 3-Years
1%
CAGR 5-Years
9%
CAGR 10-Years
15%
SK Bioscience Co Ltd
KRX:302440
Cash from Operating Activities
â‚©29.3B
CAGR 3-Years
-38%
CAGR 5-Years
15%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash from Operating Activities
â‚©133.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Operating Activities
â‚©122.7B
CAGR 3-Years
28%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Operating Activities
â‚©21.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

EuBiologics Co Ltd
Glance View

Market Cap
435.3B KRW
Industry
Biotechnology

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Intrinsic Value
17 631.48 KRW
Undervaluation 32%
Intrinsic Value
Price
E

See Also

What is EuBiologics Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
21B KRW

Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Cash from Operating Activities amounts to 21B KRW.

What is EuBiologics Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
18%

Over the last year, the Cash from Operating Activities growth was 13%.

Back to Top